Business Context and Reporting Period
This Form 8-K Current Report is filed by Healthcare Trust, Inc. (not National Healthcare Properties, Inc.) for the reporting period of October 1, 2021. The filing details the entry into a material definitive agreement for an underwritten public offering of preferred stock and related amendments to the company's operating partnership agreement and articles of incorporation.
Key Financial Metrics and Capital Structure
- Offering Size: 3,200,000 shares of 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock.
- Offering Price: $25.00 per share.
- Expected Net Proceeds: Approximately $77.5 million (after underwriting discount, excluding other estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 480,000 shares.
- Dividend Rate: 7.125% per annum ($1.78125 per share).
- Liquidation Preference: $25.00 per share.
- Seniority: Ranks on parity with the 7.375% Series A Preferred Stock and senior to Common Stock.
Material Changes and Use of Proceeds
The primary material change is the authorization and issuance of the Series B Preferred Stock. The net proceeds from the offering are designated for the following uses:
- Repayment of amounts outstanding under the company's revolving credit facility as required by the facility terms.
- General corporate purposes, including the purchase of additional properties, if the revolving credit facility is fully repaid.
- The company may subsequently re-borrow amounts repaid to the credit facility for general corporate purposes.
Outlook, Risks, and Unusual Items
Redemption Terms: The Series B Preferred Stock is redeemable at the company's option on or after October 6, 2026, at $25.00 per share plus accrued dividends. Early redemption is permitted upon a Delisting Event or Change of Control.
Delisting Event Penalty: If a Delisting Event occurs, the dividend rate increases by 2.00% per annum to 9.125% ($2.28125 per share) until the event is cured.
Voting Rights: Holders generally have no voting rights unless six or more quarterly dividends are in arrears, at which point they may elect two additional directors.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risk factors outlined in the company's 2020 Form 10-K.
Investor Verification Checklist
- Verify the final closing date of the offering (scheduled for October 6, 2021) and the actual net proceeds received.
- Confirm the extent to which proceeds were used to repay the revolving credit facility versus general corporate purposes.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification liabilities and underwriting discounts.
- Monitor the company's ability to maintain listing status to avoid the 9.125% dividend penalty rate.
- Check subsequent filings for the exercise of the 480,000 share over-allotment option.